Adamantyl Diamide Derivatives for mGluR5 Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for central nervous system disorders using glutamate receptor modulators face limitations such as low brain penetration, insufficient selectivity, potential receptor desensitization, and prolonged receptor blockade, highlighting the need for more selective and controlled modulation of metabotropic glutamate receptor 5 (mGluR5) for improved therapeutic outcomes.
Innovation Solution
Development of adamantyl diamide derivatives that act as allosteric modulators of mGluR5 receptors, offering a pharmaceutical composition and treatment method to selectively and effectively modulate the receptor, enhancing the therapeutic window for central nervous system disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glutamate analogs targeting the orthosteric binding site are used, then receptor occupancy is achieved, but brain penetration is low and selectivity with respect to different mGluR subtypes is insufficient
Solution Approach 1:
The patent employs an adamantane scaffold as a structural intermediary that mediates between the requirement for receptor occupancy and the need for improved brain penetration and selectivity. The rigid adamantane core with specific substituent positioning (R1 and R2 groups) acts as a molecular mediator that achieves selective binding to mGluR5 while facilitating better pharmacokinetic properties including brain penetration.
2Duration of action of moving object
If synthetic agonists are designed to be metabolically stable, then continuous stimulation of the receptor is achieved, but receptor desensitization occurs
Solution Approach 1:
The patent applies dynamic modulation by designing compounds that can transition between different binding modes and functional outcomes. The adamantane-derived compounds can act as agonists, antagonists, or allosteric modulators depending on their specific structure and binding context, allowing the system to adapt and avoid continuous stimulation that leads to desensitization.
3Duration of action of stationary object
If synthetic antagonists are used, then prolonged blockade of receptor function is achieved, but this may not be compatible with the kinetics of the pathology of a central nervous system disorder
Solution Approach 1:
The patent utilizes parameter changes by systematically varying the substituent groups (R1 and R2) on the adamantane scaffold to modulate the duration and intensity of receptor blockade. By changing chemical parameters such as substituent type, position, and stereochemistry, the compounds can be tuned to achieve blockade durations that match the kinetic requirements of different CNS pathologies.
Data Source
AI summary
The present invention provides adamantyl-diamide derivatives of formula (I): wherein R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof; and pharmaceutical compositions and methods using the same